ABIONYX Pharma Finalizes the Structuring of Its CER-001 Bioproduction Chain Through a Strategic Partnership with AXPLORA, Marking a Major Milestone Toward Its Potential Commercialization

Posted on by sHq_LoGiNz

TOULOUSE, France & FULLERTON, Calif.–(BUSINESS WIRE)–Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – eligible for the PEA PME), a next-generation biopharmaceutical company developing innovative treatments for sepsis and intensive care based on a proprietary apoA-I technology platform, today announced a strategic manufacturing partnership with AXPLORA, a global Contract Development and Manufacturing Organization (CDMO), to apply its specialist purification expertise to recombinant huma

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance (opens in a new tab)
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.